News
HRTX
0.4908
-1.64%
-0.0082
Here are the major earnings before the open Monday
Seeking Alpha · 9h ago
Heron Therapeutics Q2 2026 Earnings Preview
Seeking Alpha · 2d ago
Weekly Report: what happened at HRTX last week (0727-0731)?
Weekly Report · 6d ago
Weekly Report: what happened at HRTX last week (0720-0724)?
Weekly Report · 07/27 09:37
Weekly Report: what happened at HRTX last week (0713-0717)?
Weekly Report · 07/20 09:36
New Strong Sell Stocks for July 15th
NASDAQ · 07/15 10:24
Weekly Report: what happened at HRTX last week (0706-0710)?
Weekly Report · 07/13 09:36
Weekly Report: what happened at HRTX last week (0629-0703)?
Weekly Report · 07/06 09:38
Weekly Report: what happened at HRTX last week (0622-0626)?
Weekly Report · 06/29 09:36
Heron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
TipRanks · 06/25 21:36
Weekly Report: what happened at HRTX last week (0615-0619)?
Weekly Report · 06/22 09:40
Heron Shareholders Approve Directors, Incentive Plans, Tax Measures
TipRanks · 06/16 19:17
Weekly Report: what happened at HRTX last week (0608-0612)?
Weekly Report · 06/15 09:41
Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)
Seeking Alpha · 06/10 13:00
Heron Therapeutics (HRTX) Receives a Buy from H.C. Wainwright
TipRanks · 06/08 10:36
Weekly Report: what happened at HRTX last week (0601-0605)?
Weekly Report · 06/08 09:38
X4, TripAdvisor, Heron, DigitalOcean, Shake Shack Trending
TipRanks · 06/06 09:01
Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday
Benzinga · 06/03 12:52
Heron Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 06/03 11:37
Heron Therapeutics Price Target Cut to $2.00/Share From $4.00 by HC Wainwright & Co.
Dow Jones · 06/03 11:37
More
Webull provides a variety of real-time HRTX stock news. You can receive the latest news about Heron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.